Zacks Investment Research upgraded shares of AmpliPhi Biosciences Corp. (APHB) from N/A to NEUTRAL on August 04, 2014, with a target price of $0.45.
We are initiating coverage of AmpliPhi Biosciences Corp. (OTC: APHB) with a Neutral rating and a $0.45 price target. AmpliPhi is developing bacteriophage therapies for the treatment of infectious diseases. The company has three lead compounds, one for the treatment of P. aeruginosa infections in cystic fibrosis, one for the treatment of methicillin resistant S. aureus (MRSA), and one for the treatment of C. difficile infection. We believe AmpliPhi has an exciting technology but we have assigned a Neutral rating on the stock due to how early in development the company is with their lead products. We recommend investors keep the stock on their watch list as the company moves into the clinic in the next 6-12 months.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on AmpliPhi Biosciences Corp. (APHB),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment